EyePoint(EYPT)制药公司10月28日夜盘大跌5.12%,引发市场广泛关注。消息显示,此前EyePoint宣布公开发行价值1亿美元的新股,这可能是导致股价下跌的主要原因。
根据公告,此次发行由摩根大通、花旗集团和古根海姆证券三家公司联合担任簿记管理人。新发行的股票将增加公司股票供应量并导致股权被进一步稀释,因此引发了投资者担忧。盘后股价一度下跌8.5%至11.09美元。
不过,EyePoint的糖尿病黄斑水肿药物Duravyu在临床试验中取得积极进展,公司表示将利用此次发行所得资金继续推进该药物的开发工作,并支持早期管线产品的研发。但该利好消息似乎并未抵消股权稀释对股价的冲击。EyePoint目前市值约为6.49亿美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.